Juvisync

Coronary heart disease, prophylaxis of cardiovascular event, Diabetes + 11 more

Treatment

19 FDA approvals

20 Active Studies for Juvisync

What is Juvisync

Simvastatin

The Generic name of this drug

Treatment Summary

Simvastatin, which is also known as Zocor, is a medication used to lower the risk of cardiovascular disease. It belongs to a class of drugs called statins, which are used to reduce cholesterol levels in the body by blocking an enzyme that helps produce cholesterol in the liver. Simvastatin and other statin drugs are commonly prescribed following any cardiovascular events and for people with a moderate to high risk for developing CVD. Studies have shown that statins can reduce the risk of heart attack, stroke, and other cardiovascular events by 20-22%, and they have few side effects or long-term risks. There are

Zocor

is the brand name

image of different drug pills on a surface

Juvisync Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Zocor

Simvastatin

1991

620

Approved as Treatment by the FDA

Simvastatin, otherwise called Zocor, is approved by the FDA for 19 uses like Diabetes Mellitus and Homozygous Familial Hypercholesterolemia .

Diabetes Mellitus

Homozygous Familial Hypercholesterolemia

Used to treat Homozygous Familial Hypercholesterolaemia (HoFH) in combination with Ezetimibe

Hypercholesterolemia

Used to treat Heterozygous Familial Hypercholesterolemia (HeFH) in combination with Ezetimibe

Mixed Hyperlipidemia

Used to treat Mixed Hyperlipidemia in combination with Ezetimibe

Diet

Used to treat Diet in combination with Ezetimibe

Lipid-Lowering Therapy

Used to treat Lipid-Lowering Therapy in combination with Ezetimibe

Homozygous Familial Hypercholesterolaemia (HoFH)

Used to treat Homozygous Familial Hypercholesterolaemia (HoFH) in combination with Ezetimibe

history of stroke or other cerebrovascular disease cardiovascular event

prophylaxis of cardiovascular event

Heterozygous Familial Hypercholesterolemia (HeFH)

Used to treat Heterozygous Familial Hypercholesterolemia (HeFH) in combination with Ezetimibe

Physical Activity

Used to treat Exercise in combination with Ezetimibe

history of coronary heart disease cardiovascular event

Cardiovascular Events

cholesterol

Helps manage High Cholesterol

Peripheral Vascular Disease Patient

Diabetes

Coronary heart disease

Peripheral Vascular Disease

Cerebrovascular Disorders

Effectiveness

How Juvisync Affects Patients

Simvastatin is a drug taken to lower cholesterol levels. It reduces LDL cholesterol, apolipoprotein B, non-HDL cholesterol and triglyceride concentrations, while increasing HDL cholesterol levels. High LDL cholesterol, low HDL cholesterol, and high triglycerides are linked to an increased risk of heart disease. Studies have shown that taking simvastatin can reduce the risk of developing heart disease or having a fatal or non-fatal cardiovascular event, even for those with a low risk for such events. However, it can cause muscle pain, tenderness or weakness, as well as occasional liver enzyme abnormalities. It can also

How Juvisync works in the body

Simvastatin is a medication used to help reduce cholesterol. It works by blocking an enzyme in the liver that is responsible for producing cholesterol. This forces the liver to increase its production of LDL and VLDL receptors, which increases the amount of cholesterol absorbed by the liver. Simvastatin also has some other beneficial effects on the body, such as improving endothelial function and reducing inflammation and oxidative stress. It has also been found to bind to a protein that helps regulate T-cell activation in the body.

When to interrupt dosage

The prescribed dosage of Juvisync is dependent on the diagnosed affliction, including Hypercholesterolemia, Diet and Type 2 Diabetes. The magnitude of dosage can be found in the table below, contingent upon the approach of administration.

Condition

Dosage

Administration

Mixed Hyperlipidemia

, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL

Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular

Peripheral Vascular Disease

, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL

Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular

Coronary heart disease

, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL

Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular

prophylaxis of cardiovascular event

, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL

Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular

Diabetes

, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL

Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular

Cardiovascular Events

, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL

Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular

Physical Activity

, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL

Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular

Type 2 Diabetes

, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL

Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular

cholesterol

, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL

Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular

Diet

, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL

Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular

Lipid-Lowering Therapy

, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL

Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular

Hypercholesterolemia

, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL

Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular

Cerebrovascular Disorders

, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL

Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular

Homozygous Familial Hypercholesterolemia

, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL

Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular

Warnings

Juvisync Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Liver Diseases

Do Not Combine

There are 20 known major drug interactions with Juvisync.

Common Juvisync Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The serum concentration of Abemaciclib can be increased when it is combined with Simvastatin.

Amitriptyline

Major

The metabolism of Amitriptyline can be decreased when combined with Simvastatin.

Amoxapine

Major

The metabolism of Amoxapine can be decreased when combined with Simvastatin.

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Simvastatin.

Axitinib

Major

The serum concentration of Axitinib can be increased when it is combined with Simvastatin.

image of a doctor in a lab doing drug, clinical research

Juvisync Novel Uses: Which Conditions Have a Clinical Trial Featuring Juvisync?

Currently, 756 active trials are assessing the efficacy of Juvisync in improving Cerebrovascular Disorders, as well as Type 2 Diabetes and Physical Activity levels.

Condition

Clinical Trials

Trial Phases

Type 2 Diabetes

167 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1

Diabetes

74 Actively Recruiting

Phase 1, Not Applicable, Phase 4, Phase 2, Phase 3

Homozygous Familial Hypercholesterolemia

2 Actively Recruiting

Phase 3

cholesterol

4 Actively Recruiting

Phase 3, Not Applicable

prophylaxis of cardiovascular event

0 Actively Recruiting

Physical Activity

24 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Hypercholesterolemia

4 Actively Recruiting

Phase 1, Phase 3

Lipid-Lowering Therapy

0 Actively Recruiting

Cerebrovascular Disorders

2 Actively Recruiting

Phase 1, Not Applicable

Diet

5 Actively Recruiting

Not Applicable, Phase 1

Cardiovascular Events

4 Actively Recruiting

Not Applicable

Coronary heart disease

0 Actively Recruiting

Mixed Hyperlipidemia

0 Actively Recruiting

Peripheral Vascular Disease

6 Actively Recruiting

Phase 1, Phase 2, Not Applicable, Phase 4, Phase 3

Patient Q&A Section about juvisync

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Clinical Trials for Juvisync

Image of VA Greater Los Angeles Healthcare System, West Los Angeles, CA in West Los Angeles, United States.

EBQI Strategies for Women's Health

Any Age
All Sexes
West Los Angeles, CA

Women Veterans are the fastest growing segment of VA users, with most users in midlife. This dramatic growth has created challenges for VA to ensure that appropriate services are available to meet women Veterans' needs, and that they will want and be able to use those services. Furthermore, few VA improvement efforts have focused on women Veterans' health and health care in midlife. The EMPOWER QUERI 3.0 Program is a cluster randomized type 3 hybrid implementation-effectiveness trial testing two strategies designed to support implementation and sustainment of evidence-based practices for women Veterans in at least 18 VA facilities from 4 regions.

Waitlist Available
Has No Placebo

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Erin P Finley, PhD MPH

Image of Faculty of Health Sciences in Winnipeg, Canada.

Saskatoon Berries for Type 2 Diabetes

18 - 74
All Sexes
Winnipeg, Canada

Diabetes becomes epidemic in worldwide countries. Diabetes Canada indicated that 30% of adults in Manitoba are diabetes or prediabetes. Nine out of ten diabetic patients are type 2 diabetes (T2D). T2D is characterized by insulin resistance and obesity. Uncontrolled diabetes leads to serious consequences including heart attack, stroke, chronic renal failure, liver failure, blindness and low limb amputation. Most of hypoglycemic medications have certain side effects. Natural foods or nutraceuticals with hypoglycemic potential are expected to provide a safer management for diabetic patients. Saskatoon berry is a popular fruit in Canadian Prairie and Northern states in USA. Our previous studies demonstrated Saskatoon berry (SB) powder attenuated hyperglycemia, hyperlipidemia, insulin resistance, inflammation, liver steatosis and gut dysbiosis in diet-induced insulin resistant mice, a model for T2D. The findings of the glucose and lipid lowering or liver protective effects of SB powder have been supported by another group in Australia in high fat fed rats. Our preliminary studies in 20 healthy subjects demonstrated that dried whole SB (40 g/day for 10 weeks) significantly reduced fasting plasma glucose, total and LDL-cholesterol, systolic blood pressure, and increased plasma glucagon-like peptide compared to baseline, which was associated with increased intake of total fiber and decreased intake of saturated fat. The changes in metabolic and vascular variables significantly correlated with the alterations in gut microbiota The combination of findings suggest that SB is good candidate of prebiotic functional food as a supplemental remedy for reducing the risk for metabolic syndrome and preventing or managing T2D. The effect of Saskatoon berry and its products on metabolic disorders have not been studied in diabetic subjects. We propose to examine the effects of oral administration of freeze-dried whole SB on glucose metabolism, insulin resistance and gut microbiota in untreated prediabetes and new type 2 diabetic patients compared to a control dried fruit in a randomized controlled trial.

Waitlist Available
Dietary Supplement

Faculty of Health Sciences

Image of Central Research Associates - Flourish - PPDS in Birmingham, United States.

CX11 for Type 2 Diabetes

18 - 75
All Sexes
Birmingham, AL

This study is testing whether a new medication called CX11 works and is safe for participants with type 2 diabetes who have not reached good blood sugar control while taking a steady dose of metformin, with or without a steady dose of an SGLT2 inhibitor, for at least 90 days. The study is being done at multiple medical centers. Participants are assigned by chance (randomized) to different groups, and neither the participants nor the study staff know which group they're in (double-blind). The groups are compared side by side (parallel), and some participants will receive inactive pills (placebo) to help measure the true effect of the study drug. After screening, participants will be randomly placed into one of six groups, with equal chances of being in any group. Each group will receive a different dose of CX11 or a placebo. Treatment will last 24 weeks. After that, all participants will have a 2-week follow-up period to check on safety.

Phase 2
Waitlist Available

Central Research Associates - Flourish - PPDS (+29 Sites)

Corxel Pharmaceuticals

Have you considered Juvisync clinical trials?

We made a collection of clinical trials featuring Juvisync, we think they might fit your search criteria.
Go to Trials
Image of Brigham and Women's Hospital in Boston, United States.

Rosuvastatin for Cancer-Associated Blood Clots

18+
All Sexes
Boston, MA

Patients with cancer are at high risk for life-threatening venous thromboembolism (VTE) yet rarely receive anticoagulant prophylaxis due to bleeding risks. Thus, effective prophylaxis in oncology requires a method to reduce VTE without increasing hemorrhage. The primary aim of the Statin Therapy to Prevent Cancer Associated Venous Thromboembolism (STAT-CAT) trial is to test whether rosuvastatin 20 mg daily for 12 months compared to placebo can safely prevent VTE in patients with newly diagnosed or recently relapsed cancer who are at increased thrombotic risk, are not planned to be anticoagulated, and who do not otherwise take statin therapy.

Phase 4
Waitlist Available

Brigham and Women's Hospital (+1 Sites)

Image of Duke Center for Living in Durham, United States.

Glucagon for Diabetes

18 - 45
All Sexes
Durham, NC

This study examines how glucagon works to regulate glucose metabolism, based on new findings that suggest glucagon signaling in the liver has more than one role, and that these multiple roles can be opposing in nature. Understanding this biology provides an opportunity to develop new generations of glucagon-based drugs that target specific pathways, making them more effective at controlling blood glucose. Participants will complete paired, 5-hour hyperinsulinemic glucose clamp visits in which they receive either glucagon or saline infusions while blood glucose is maintained and frequent blood samples are collected. The primary focus is whether coordinated glucagon and insulin signaling enhances hepatic insulin sensitivity.

Phase 1 & 2
Waitlist Available

Duke Center for Living

David D'Alessio, MD

Have you considered Juvisync clinical trials?

We made a collection of clinical trials featuring Juvisync, we think they might fit your search criteria.
Go to Trials
Image of NYU Langone Health in New York, United States.

Adaptive Dietary Intervention for Type 2 Diabetes

18+
All Sexes
New York, NY

The investigators will examine the feasibility, acceptability, and effect of an adaptive dietary intervention over 24 weeks (12-week intervention, 12-week follow-up) among Asian Americans with Type 2 diabetes. Participants (N=120; 60 Chinese Americans and 60 Vietnamese Americans) will be 2:1 randomized to one of two arms: adaptive dietary intervention or standard of care (SC). The intervention will begin with continued glucose monitoring (CGM) use only during weeks 0-4. At week 4, participants who achieve the glycemic control goal (at least an 8% increase in time in range \[TIR\] from baseline) will continue with the CGM alone during weeks 4-12 ("CGM Alone"); otherwise, culturally and linguistically adapted glucose excursion minimization (GEM) will be augmented with CGM ("CGM-GEM").

Waitlist Available
Has No Placebo

NYU Langone Health

Yaguang Zheng, PhD, RN

Have you considered Juvisync clinical trials?

We made a collection of clinical trials featuring Juvisync, we think they might fit your search criteria.
Go to Trials